Apellis Pharmaceuticals Inc at Evercore ISI HealthCONx Conference Transcript

Nov 28, 2023 / 03:00PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Okay. Excellent. Well, listen, Tim, why don't you kick it off? We'll jump right in. I think we have Jazz coming up in about 15 minutes, but jump right in.

Timothy E. Sullivan - Apellis Pharmaceuticals, Inc. - CFO & Treasurer

Sure. Sure.

Questions and Answers:

Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

So let's start with the latest update. Where are we right now in commercial launch and in the debates of the day?

Timothy E. Sullivan - Apellis Pharmaceuticals, Inc. - CFO & Treasurer

Sure. So in the third quarter, we announced that we had $75 million in revenue of SYFOVRE, we had $24 million in revenue with EMPAVELI. So the launch is underway. And as you probably all saw or most of you saw from our third quarter earnings, we had a nice rebound in our revenue and our
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot